Verve Therapeutics Return on Equity

Verve Therapeutics (VERV) currently reports a ROE of -38.23%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Verve Therapeutics's ROE history and peer comparisons.

Verve Therapeutics's ROE of -38.23% is lower than the Healthcare sector average of 22.01%. That is roughly 273.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Verve Therapeutics's current -38.23% should be judged against Healthcare norms (sector average: 22.01%) and against VERV's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -38.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Verve Therapeutics, and consider following VERV for alerts when major investors trade the stock.

Verve Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -38.23% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VERV with unrelated industries.